Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1.

2.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M.

J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.

3.

Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.

Ielpo B, Duran H, Diaz E, Fabra I, Caruso R, Ferri V, Malavé L, Hidalgo M, Alvarez R, Plaza C, Quijano Y, Vicente E.

Eur J Surg Oncol. 2016 Sep;42(9):1394-400. doi: 10.1016/j.ejso.2016.01.006. Epub 2016 Jan 29.

PMID:
26899943
4.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.

Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.

PMID:
23053263
5.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A.

Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22.

6.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, McGovern D, Lu B, Von Hoff DD.

Ann Oncol. 2016 Apr;27(4):648-53. doi: 10.1093/annonc/mdw020. Epub 2016 Jan 22.

7.

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, Schwarz MA, Schwarz RE.

Carcinogenesis. 2013 Oct;34(10):2361-9. doi: 10.1093/carcin/bgt227. Epub 2013 Jun 26.

8.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA.

Cancer Discov. 2012 Mar;2(3):260-9. doi: 10.1158/2159-8290.CD-11-0242. Epub 2012 Feb 28.

9.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD.

J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb.

PMID:
25638248
10.
11.

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.

Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD.

Clin Cancer Res. 2015 Nov 1;21(21):4811-8. doi: 10.1158/1078-0432.CCR-14-3222. Epub 2015 Jul 13. Erratum in: Clin Cancer Res. 2016 Dec 15;22(24):6302.

12.

Treatment of metastatic pancreatic adenocarcinoma: a review.

Thota R, Pauff JM, Berlin JD.

Oncology (Williston Park). 2014 Jan;28(1):70-4. Review.

13.

Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.

Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, Nakajima TE, Furuse J.

Cancer Chemother Pharmacol. 2016 Mar;77(3):595-603. doi: 10.1007/s00280-016-2972-3. Epub 2016 Feb 3.

PMID:
26842789
14.

Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.

Reni M, Wan Y, Solem C, Whiting S, Ji X, Botteman M.

J Med Econ. 2014 May;17(5):338-46. doi: 10.3111/13696998.2014.903122. Epub 2014 Mar 21.

PMID:
24654922
15.

Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.

Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M.

Cancer Treat Rev. 2014 Feb;40(1):118-28. doi: 10.1016/j.ctrv.2013.04.004. Epub 2013 Jul 9. Review.

PMID:
23849556
16.

A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.

Cohen SJ, O'Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L.

Cancer Chemother Pharmacol. 2016 Apr;77(4):693-701. doi: 10.1007/s00280-016-2981-2. Epub 2016 Feb 17.

PMID:
26886016
17.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.

Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group..

BMC Cancer. 2015 Oct 6;15:653. doi: 10.1186/s12885-015-1656-4.

18.

Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.

John P, Butler H, Saif MW.

Anticancer Res. 2014 Dec;34(12):7267-70.

PMID:
25503159
19.

Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.

Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1065-72. doi: 10.1007/s00280-013-2102-4. Epub 2013 Mar 13.

PMID:
23483298
20.

First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice.

Vogel A, Pelzer U, Salah-Eddin AB, Köster W.

In Vivo. 2014 Nov-Dec;28(6):1135-40.

PMID:
25398812

Supplemental Content

Support Center